SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer

Rebecca Johnson, Nirupama Sabnis, Xiangle Sun, Ruhani Ahluwalia, Andras G. Lacko

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalBreast Cancer: Targets and Therapy
Volume9
DOIs
StatePublished - 2 Jun 2017

Keywords

  • Breast cancer
  • Lapatinib
  • RHDL nanoparticles
  • SR-B1 receptors
  • TNBC
  • Targeted drug delivery
  • Valrubicin

Fingerprint Dive into the research topics of 'SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer'. Together they form a unique fingerprint.

  • Cite this